Examining the role of insulin in the regulation of cardiovascular health

Future Cardiology

Volumn 9, Issue 1, 2013, Pages 39-52

  Salt, Ian P ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

cardiovascular; diabetes; endothelin; endothelium; insulin; nitric oxide

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; C PEPTIDE; CAVEOLIN 1; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEAT SHOCK PROTEIN 90; INSULIN; INSULIN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; METFORMIN; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SHC; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C RECEPTOR; TYROSINE KINASE RECEPTOR;

ADIPOSE TISSUE; ATHEROGENESIS; AUTOPHOSPHORYLATION; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIMERIZATION; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIUM; ENDOTHELIUM CELL; ERYTHROCYTE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HEART MUSCLE CELL; HUMAN; HYPERINSULINEMIA; INSULIN BINDING; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; THROMBOCYTE; VASODILATATION;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN; INSULIN RESISTANCE; MUSCLE, SMOOTH, VASCULAR;

EID: 84871579070     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.12.77     Document Type: Review

References (85)

1. Rask-Madsen C, Kahn R. Tissue-specific insulin signalling, metabolic syndrome, and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 32(9), 2052-2059 (2012).
2. Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 15(5), 635-645 (2012).
3. Xu J, Zou MH. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation 120(13), 1266-1286 (2009).
4. DeFronzo RA. Insulin resistance, lipotoxicity, Type 2 diabetes and atherosclerosis: the missing links. Diabetologia 53(7), 1270-1287 (2010).
5. Leto D, Saltiel AR. Regulation of glucose transport by insulin: traffic control of GLUT4. Nat. Rev. Cell Biol. 13(6), 383-396 (2012).
6. Siddle K. Molecular basis of signaling specificity of insulin and IGF receptors: neglected corners and recent advances. Front. Endocrinol. 3, 34 (2012).
7. Potenza MA, Addabbo F, Montagnani M. Vascular actions of insulin with implications for endothelial dysfunction. Am. J. Physiol. Endocrinol. Metab. 297(3), E568-E577 (2009).
8. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J. Clin. Invest. 94, 1172-1174 (1994).
9. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J. Clin. Invest. 94(6), 2511-2515 (1994).
10. Barrett EJ, Eggleston EM, Inyard AC et al. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia 52(5), 752-764 (2009).
11. Abel ED, O'Shea KM, Ramasamy R. Insulin resistance: metabolic mechanisms and consequences in the heart. Arterioscler. Thromb. Vasc. Biol. 32(9), 2068-2076 (2012).
12. Boudina S, Bugger H, Sena S et al. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 119(9), 1272-1283 (2009).
13. Liu J, Jahn LA, Fowler DE, Barrett EJ, Cao W, Liu Z. Free fatty acids induce insulin resistance in both cardiac and skeletal muscle microvasculature in humans. J. Clin. Endocrinol. Metab. 96(2), 438-446 (2011).
14. von Lewinski D, Rainer PP, Gasser R et al. Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients. Metabolism 59(7), 1020-1028 (2010).
15. Ng KW, Allen ML, Desai A, Macrae D, Pathan N. Cardioprotective effects of insulin: how intensive insulin therapy may benefit cardiac surgery patients. Circulation 125(5), 721-728 (2012).
16. Ellsworth ML, Ellis CG, Goldman D, Stephenson AH, Dietrich HH, Sprague RS. Erythrocytes: oxygen sensors and modulators of vascular tone. Physiology 107-116 (2009).
17. Hanson MS, Ellsworth ML, Achilleus D et al. Insulin inhibits low oxygen-induced ATP release from human erythrocytes: implication for vascular control. Microcirculation 16(5), 424-433 (2009).
18. Randriamboavonjy V, Schrader J, Busse R, Fleming I. Insulin induces the release of vasodilator compounds from platelets by a nitric oxide-G kinase-VAMP-3-dependent pathway. J. Exp. Med. 199(3), 347-356 (2004).
19. Worthley MI, Holmes AS, Willoughby SR et al. The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production, resolution with intensive insulin administration. J. Am. Coll. Cardiol. 49(3), 304-310 (2007).
20. Kobayashi T, Nogami T, Taguchi K, Matsumoto T, Kamata K. Diabetic state, high plasma insulin and angiotensin II combine to augment endothelin-1-induced vasoconstriction via ETA receptors and ERK. Br. J. Pharmacol. 155(7), 974-983 (2008).
21. Michel T, Vanhoutte PM. Cellular signalling and NO production. Pflugers Arch. 459(6), 807-816 (2010).
22. Abbas A, Imrie H, Viswambharan H et al. The insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium. Diabetes 60(8), 2169-2178 (2011).
23. Imrie H, Viswambharan H, Sukumar P et al. Novel role of the IGF-1 receptor in endothelial function and repair: studies in endothelium-targeted IGF-1 receptor transgenic mice. Diabetes 61(9), 2359-2368 (2012).
24. Mount PF, Kemp BE, Power DA. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J. Mol. Cell. Cardiol. 42(2), 271-279 (2007).
25. Ritchie SA, Kohlhaas CF, Boyd AR et al. Insulin-stimulated phosphorylation of endothelial nitric oxide synthase at Ser615 contributes to nitric oxide synthesis. Biochem. J. 426(1), 85-90 (2010).
26. Kohlhaas CF, Morrow VA, Jhakra N et al. Insulin rapidly stimulates l-arginine transport in human aortic endothelial cells via Akt. Biochem. Biophys. Res. Commun. 412(4), 747-751 (2011).
27. Fleming I. Molecular mechanisms underlying the activation of eNOS. Eur. J. Physiol. 459(6), 793-806 (2010).
28. Wang H, Wang AX, Liu Z, Chai W, Barrett EJ. The trafficking/interaction of eNOS and caveolin-1 induced by insulin modulates endothelial nitric oxide production. Mol. Endocrinol. 23(10), 1613-1623 (2009).
29. Zhang QJ, Holland WL, Wilson L et al. Ceramide mediates vascular dysfunction in diet-induced obesity by PP2A-mediated dephosphorylation of the eNOS-Akt complex. Diabetes 61(7), 1848-1859 (2012).
30. González M, Gallardo V, Rodríguez N et al. Insulin-stimulated l-arginine transport requires SLC7A1 gene expression and is associated with human umbilical vein relaxation. J. Cell. Physiol. 226(11), 2916-2924 (2011).
31. Anderssohn M, Schwedhelm E, Lüneburg N, Vasan RS, Böger RH. Assymetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus. Diab. Vasc. Dis. Res. 7(2), 105-118 (2010).
32. Cunnington C, Channon KM. Tetrahydrobiopterin: pleiotropic roles in cardiovascular pathophysiology. Heart 96(23), 1872-1877 (2010).
33. Ji L, Fu F, Zhang L et al. Insulin attenuates myocardial ischemia/reperfusion injury via reducing oxidative/nitrative stress. Am. J. Physiol. Endocrinol. Metab. 298(4), E871-E880 (2010).
34. Duncan ER, Crossey PA, Walker S et al. Effect of endothelium-specific insulin resistance on endothelial function in vivo. Diabetes 57(12), 3307-3314 (2008).
35. Ishii M, Shimizu S, Nagai T, Shiota K, Kiuchi Y, Yamamoto T. Stimulation of tetrahydrobiopterin synthesis induced by insulin: possible involvement of phosphatidylinositol 3-kinase. Int. J. Biochem. Cell Biol. 33(1), 65-73 (2001).
36. Haines RJ, Corbin KD, Pendleton LC, Meininger CJ, Eichler DC. Insulin transcriptionally regulates argininosuccinate synthase to maintain vascular endothelial function. Biochem. Biophys. Res. Commun. 421(1), 9-14 (2012).
37. Vicent D, Ilany J, Kondo T et al. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J. Clin. Invest. 111(9), 1373-1380 (2003).
38. Fisslthaler B, Loot AE, Mohamed A, Busse R, Fleming I. Inhibition of endothelial nitric oxide synthase activity by proline-rich tyrosine kinase 2 in response to fluid shear stress and insulin. Circ. Res. 102(12), 1520-1528 (2008).
39. Mazzuca MQ, Khalil RA. Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease. Biochem. Pharmacol. 84(2), 147-162 (2012).
40. Wang Y, Cheng KK, Lam KS et al. APPL1 counteracts obesity-induced vascular insulin resistance and endothelial dysfunction by modulating the endothelial production of nitric oxide and endothelin-1 in mice. Diabetes 60(11), 3044-3054 (2011).
41. Kapakos G, Bouallegue A, Daou GB, Srivastava AK. Modulatory role of nitric oxide/cGMP system in endothelin-1-induced signaling responses in vascular smooth muscle cells. Curr. Cardiol. Rev. 6(4), 247-254 (2010).
42. Liu Y, Petreaca M, Martins-Green M. Cell and molecular mechanisms of insulin-induced angiogenesis. J. Cell. Mol. Med. 13(11-12), 4492-4504 (2009).
43. Waldow T, Witt W, Weber E, Matschke K. Nitric oxide donor-induced persistent inhibition of cell adhesion protein expression and NFkB activation in endothelial cells. Nitric Oxide 15(2), 103-113 (2006).
44. Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Insulin as an anti-inflammatory and antiatherogenic modulator. J. Am. Coll. Cardiol. 53(5 Suppl. ), S14-S20 (2009).
45. Wang H, Wang AX, Liu Z, Barrett EJ. Insulin signaling stimulates insulin transport by bovine aortic endothelial cells. Diabetes 57(3), 540-547 (2008).
46. Chiu JD, Richey JM, Harrison LN et al. Direct administration of insulin into skeletal muscle reveals that the transport of insulin across the capillary endothelium limits the time course of insulin to activate glucose disposal. Diabetes 57(4), 828-835 (2008).
47. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr. Rev. 28(5), 463-491 (2007).
48. Lee JH, Ragolia L. AKT phosphorylation is essential for insulin-induced relaxation of rat vascular smooth muscle cells. Am. J. Physiol. Cell. Physiol. 291(6), C1355-C1365 (2006).
49. Lee JH, Palaia T, Ragolia L. Impaired insulin-stimulated myosin phosphatase Rho-interacting protein signaling in diabetic Goto-Kakizaki vascular smooth muscle cells. Am. J. Physiol. Cell. Physiol. 302(9), C1371-C1381 (2012).
50. Isenovic ER, Kedees MH, Haidara MA, Trpkovic A, Mikhailidis DP, Marche P. Involvement of ERK1/2 kinase in insulin-and thrombin-stimulated vascular smooth muscle cell proliferation. Angiology 61(4), 357-364 (2010).
51. Lightell DJ Jr, Moss SC, Woods TC. Loss of canonical insulin signaling accelerates vascular smooth muscle cell proliferation and migration through changes in p27Kip1 regulation. Endocrinology 152(2), 651-658 (2011).
52. Liang CP, Han S, Senokuchi T, Tall AR. The macrophage at the crossroads of insulin resistance and atherosclerosis. Circ. Res. 100(11), 1546-1555 (2007).
53. Mita T, Azuma K, Goto H et al. IRS-2 deficiency in macrophages promotes their accumulation in the vascular wall. Biochem. Biophys. Res. Commun. 415(4), 545-550 (2011).
54. Eringa EC, Bakker W, van Hinsbergh VW. Paracrine regulation of vascular tone, inflammation and insulin sensitivity by perivascular adipose tissue. Vascul. Pharmacol. 56(5-6), 204-209 (2012).
55. Greenstein AS, Khavandi K, Withers SB et al. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 119(12), 1661-1670 (2009).
56. Breen DM, Chan KK, Dhaliwall JK et al. Insulin increases reendothelialization and inhibits cell migration and neointimal growth after arterial injury. Arterioscler. Thromb. Vasc. Biol. 29(7), 1060-1066 (2009).
57. Han S, Liang CP, DeVries-Seimon T et al. Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. Cell Metab. 3(4), 257-266 (2006).
58. Baumgartl J, Baudler S, Scherner M et al. Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-deficient mice against atherosclerosis. Cell Metab. 3(4), 247-256 (2006).
59. Rask-Madsen C, Li Q, Freund B et al. Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell Metab. 11(5), 379-389 (2010).
60. Vasic D, Walcher D. C-peptide: a new mediator of atherosclerosis in diabetes. Mediators Inflamm. 2012, 858692 (2012).
61. Madonna R, De Caterina R. Prolonged exposure to high insulin impairs the endothelial PI3-kinase/Akt/nitric oxide signalling. Thromb. Haemost. 101(2), 345-350 (2009).
62. Li G, Barrett EJ, Ko SH, Cao W, Liu Z. Insulin and insulin-like growth factor-I receptors differentially mediate insulin-stimulated adhesion molecule production by endothelial cells. Endocrinology 150(8), 3475-3482 (2009).
63. Ardigo D, Franzini L, Valtuena S, Monti LD, Reaven GM, Zavaroni I. Relation of plasma insulin levels to forearm flow-mediated dilatation in healthy volunteers. Am. J. Cardiol. 97(8), 1250-1254 (2006).
64. Rask-Madsen C, Buonomo E, Li Q et al. Hyperinsulinemia does not change atherosclerosis development in apolipoprotein E null mice. Arterioscler. Thromb. Vasc. Biol. 32(5), 1124-1131 (2012).
65. Copps KD, White MF. Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia 55(10), 2565-2582 (2012).
66. Tabbi-Anneni I, Buchanan J, Cooksey RC, Abel ED. Captopril normalizes insulin signaling and insulin-regulated substrate metabolism in obese (ob/ob) mouse hearts. Endocrinology 149(8), 4043-4050 (2008).
67. Zhang L, Ussher JR, Oka T, Cadete VJ, Wagg C, Lopaschuk GD. Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation. Cardiovasc. Res. 89(1), 148-156 (2011).
68. Kim JA, Jang HJ, Martinez-Lemus LA, Sowers JR. Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. Am. J. Physiol. Endocrinol. Metab. 302(2), E201-E208 (2012).
69. Andreozzi F, Laratta E, Procopio C et al. Interleukin-6 impairs the insulin signaling pathway, promoting production of nitric oxide in human umbilical vein endothelial cells. Mol. Cell. Biol. 27(6), 2372-2383 (2007).
70. Li G, Barrett EJ, Barrett MO, Cao W, Liu Z. Tumor necrosis factor-a induces insulin resistance in endothelial cells via a p38 mitogen-activated protein kinase-dependent pathway. J. Biol. Chem. 284(25), 17120-17128 (2009).
71. Jung CH, Lee WJ, Hwang JY et al. Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway. Biochem. Biophys. Res. Commun. 413(2), 264-269 (2011).
72. Nemoto S, Kobayashi T, Taguchi K, Matsumoto T, Kamata K. Losartan improves aortic endothelium-dependent relaxation via proline-rich tyrosine kinase 2/Src/Akt pathway in Type 2 diabetic Goto-Kakizaki rats. Am. J. Physiol. Heart Circ. Physiol. 301(6), H2383-H2394 (2011).
73. Taguchi K, Kobayashi T, Matsumoto T, Kamata K. Dysfunction of endothelium-dependent relaxation to insulin via PKC-mediated GRK2/Akt activation in aortas of ob/ob mice. Am. J. Physiol. Heart Circ. Physiol. 301(2), H571-H583 (2011).
74. Gogg S, Smith U, Jansson PA. Increased MAPK activation and impaired insulin signaling in subcutaneous microvascular endothelial cells in Type 2 diabetes: the role of endothelin-1. Diabetes 58(10), 2238-2245 (2009).
75. Doronzo G, Russo I, Mattiello L, Riganti C, Anfossi G, Trovati M. Insulin activates hypoxia-inducible factor-1a in human and rat vascular smooth muscle cells via phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways: impairment in insulin resistance owing to defects in insulin signalling. Diabetologia 49(5), 1049-1063 (2006).
76. Lee JH, Palaia T, Ragolia L. Impaired insulin-mediated vasorelaxation in diabetic Goto-Kakizaki rats is caused by impaired Akt phosphorylation. Am. J. Physiol. Cell. Physiol. 296(2), C327-C338 (2009).
77. Nathan DM, Cleary PA, Backlund JY et al. Diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study research group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353(25), 2643-2653 (2005).
78. Gerstein HC, Bosch J, Dagenais GR et al. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. 367(4), 319-328 (2012).
79. Boyle JG, Salt IP, McKay GA. Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target. Diabet. Med. 27(10), 1097-1106 (2010).
80. Wang S, Song P, Zou MH. AMP-activated protein kinase, stress responses and cardiovascular diseases. Clin. Sci. 122(12), 555-573 (2012).
81. Boyle JG, Logan PJ, Ewart MA et al. Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase. J. Biol. Chem. 283(17), 11210-11217 (2008).
82. Ewart MA, Kohlhaas CF, Salt IP. Inhibition of tumor necrosis factor a-stimulated monocyte adhesion to human aortic endothelial cells by AMP-activated protein kinase. Arterioscler. Thromb. Vasc. Biol. 28(12), 2255-2257 (2008).
83. Balakumar P, Kathuria S. Submaximal PPARg activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders. Br. J. Pharmacol. 166(7), 1981-1992 (2012).
84. Forst T, Weber MM, Pfützner A. Cardiovascular benefits of GLP-1-based therapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control. Exp. Diabetes Res. 2012, 635472 (2012).
85. Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul. Pharmacol. 55(1-3), 10-16 (2011).